Summary
The provided statements are largely general off-label sleep-combination guidance and do not align with (or are not supported by) the only supplied FDA label content, which concerns suicidal thoughts/behaviors monitoring in pediatric/young adult patients. None of the response’s claims are specifically supported or evaluated against the supplied label text.
Category Scores
Accurate Statements
Unsupported Statements
Trazodone is an antidepressant often used off-label for insomnia.
Not supported by the supplied FDA label excerpts (only suicidal thoughts/behaviors pediatric/young adult monitoring sections were provided).
There is no single definitive rule that trazodone and melatonin must never be combined.
Not supported by the supplied FDA label excerpts.
Combining sedating sleep aids can increase the chance of next-day drowsiness.
Not supported by the supplied FDA label excerpts.
Combining sedating sleep aids can increase the chance of next-day dizziness.
Not supported by the supplied FDA label excerpts.
Combining sedating sleep aids can increase the chance of impaired coordination.
Not supported by the supplied FDA label excerpts.
When taken together, more intense next-day drowsiness or 'hangover' can occur.
Not supported by the supplied FDA label excerpts.
When taken together, dizziness or lightheadedness can occur.
Not supported by the supplied FDA label excerpts.
When taken together, slower reaction time can occur, which can affect driving or operating machinery.
Not supported by the supplied FDA label excerpts.
When taken together, an increased risk of falls can occur, especially in older adults.
Not supported by the supplied FDA label excerpts.
Unusual confusion, severe unsteadiness, or fainting are indications to stop and seek medical advice promptly.
Not supported by the supplied FDA label excerpts.
Older age or a history of falls are reasons to be extra cautious with the combination.
Not supported by the supplied FDA label excerpts.
Breathing problems such as sleep apnea or severe lung disease are reasons to be extra cautious with the combination.
Not supported by the supplied FDA label excerpts.
Drinking alcohol or taking other sedatives (including benzodiazepines, opioids, and some sleep medications) are reasons to be extra cautious with the combination.
Not supported by the supplied FDA label excerpts.
Taking medications that make you drowsy or affect heart rhythm are reasons to be extra cautious with the combination.
Not supported by the supplied FDA label excerpts.
Low blood pressure or feeling faint when standing are reasons to be extra cautious with the combination.
Not supported by the supplied FDA label excerpts.
Trazodone can interact with certain antidepressants and other medications that affect serotonin pathways.
Not supported by the supplied FDA label excerpts.
Trazodone can increase sedation when combined with other sleep aids or alcohol.
Not supported by the supplied FDA label excerpts.
Melatonin can add to sedation.
Not supported by the supplied FDA label excerpts.
Starting melatonin at a low dose is a conservative approach.
Not supported by the supplied FDA label excerpts.
Using melatonin only as needed is recommended as part of the conservative approach.
Not supported by the supplied FDA label excerpts.
Higher doses of melatonin can increase morning grogginess in some people.
Not supported by the supplied FDA label excerpts.
Trazodone dosing for sleep is individualized.
Not supported by the supplied FDA label excerpts (no dosing information provided).
If severe symptoms like fainting, trouble breathing, chest pain, or marked confusion occur, urgent medical care should be sought.
Not supported by the supplied FDA label excerpts.
Severe dizziness, worsening mood changes, or any reaction that feels out of the ordinary are reasons to seek prompt advice.
Not supported by the supplied FDA label excerpts.
Contradictions
Important Omissions
No mention of the boxed-warning-like risk of increased suicidal thoughts and behaviors in pediatric and young adult patients (age ≤24 years) or the label’s instructions to monitor all antidepressant-treated patients (especially early treatment and after dose changes) and to counsel family/caregivers to watch for changes in behavior and emergent suicidality, including possible regimen change/discontinuation if suicidal thoughts/behaviors emerge.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The response provides numerous specific cautions and symptom-triggered actions about combining trazodone with melatonin (and other sedatives) without support from the supplied FDA label excerpts. It also omits the key supplied boxed-warning content regarding suicidality monitoring in pediatric/young adult patients, which is material for safe and accurate labeling-aligned communication.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Unsupported general guidance about combining trazodone with melatonin and other sedatives, and omission of the supplied label’s suicidality monitoring/caregiver counseling content for pediatric and young adult patients.
Suggested Improvement
Limit claims to labeling-supported information from the provided sections, including: increased risk of suicidal thoughts/behaviors in patients ≤24 years, monitoring during initial months and after dose changes, caregiver counseling to monitor behavior changes, and considering changes/discontinuation if suicidal thoughts/behaviors emerge.